CORESTEM Inc Cash Flow Conversion Efficiency
CORESTEM Inc cash flow conversion efficiency. Based on the latest financial reports, CORESTEM Inc (166480) has a cash flow conversion efficiency ratio of -0.103x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.18 Billion ≈ $-2.83 Million USD) by net assets (₩40.62 Billion ≈ $27.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CORESTEM Inc (2014–2024)
Cash flow conversion efficiency of CORESTEM Inc from 2014 to 2024. This chart illustrates how CORESTEM Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 166480 share price today for real-time trading data and today's change.
CORESTEM Inc Cash Flow Conversion Ratio Explained
CORESTEM Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CORESTEM Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CORESTEM Inc ranked by their cash flow conversion efficiency. Also see CORESTEM Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
|
-13.143x |
|
Kyung Chang Industrial Co. Ltd
KQ:024910
|
0.105x |
|
Uniti SA
PA:ALUNT
|
-0.156x |
|
CID HoldCo, Inc. Common Stock
NASDAQ:DAIC
|
0.323x |
|
Pion Group AB Series B
ST:PION-B
|
-0.103x |
|
HICL Infrastructure Company Ltd
LSE:HICL
|
0.026x |
|
Gome Telecom Equipment Co Ltd
SHG:600898
|
-0.051x |
|
PTRB
KLSE:0260
|
0.084x |
Annual Cash Flow Conversion Efficiency for CORESTEM Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of CORESTEM Inc from 2014 to 2024. Review 166480 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩48.59 Billion ≈ $32.93 Million |
₩-21.12 Billion ≈ $-14.31 Million |
-0.435x | +45.73% |
| 2023-12-31 | ₩19.60 Billion ≈ $13.28 Million |
₩-15.70 Billion ≈ $-10.64 Million |
-0.801x | -294.34% |
| 2022-12-31 | ₩41.46 Billion ≈ $28.10 Million |
₩-8.42 Billion ≈ $-5.71 Million |
-0.203x | +1.23% |
| 2021-12-31 | ₩37.19 Billion ≈ $25.20 Million |
₩-7.65 Billion ≈ $-5.18 Million |
-0.206x | -290.05% |
| 2020-12-31 | ₩41.29 Billion ≈ $27.98 Million |
₩4.47 Billion ≈ $3.03 Million |
0.108x | +1260.00% |
| 2019-12-31 | ₩57.70 Billion ≈ $39.10 Million |
₩-538.08 Million ≈ $-364.65K |
-0.009x | +48.55% |
| 2018-12-31 | ₩62.24 Billion ≈ $42.18 Million |
₩-1.13 Billion ≈ $-764.48K |
-0.018x | +81.10% |
| 2017-12-31 | ₩65.60 Billion ≈ $44.46 Million |
₩-6.29 Billion ≈ $-4.26 Million |
-0.096x | -282.69% |
| 2016-12-31 | ₩66.73 Billion ≈ $45.22 Million |
₩3.50 Billion ≈ $2.37 Million |
0.053x | +424.60% |
| 2015-12-31 | ₩63.04 Billion ≈ $42.72 Million |
₩-1.02 Billion ≈ $-691.01K |
-0.016x | +87.47% |
| 2014-12-31 | ₩18.97 Billion ≈ $12.86 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.129x | -- |
About CORESTEM Inc
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more